Who are Losartan and Amlodipine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/losartan-and-amlodipine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Losartan and Amlodipine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Losartan and Amlodipine (Losartan and Amlodipine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor antagonist + Calcium channel blocker combination. Area: Cardiovascular.

marketed Angiotensin II receptor antagonist + Calcium channel blocker combination AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Losartan and Amlodipine (Losartan and Amlodipine) — Centro Universitario de Ciencias de la Salud, Mexico. Losartan blocks angiotensin II receptors to reduce vasoconstriction and aldosterone release, while amlodipine blocks calcium channels to relax blood vessels, together lowering blood pressure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Losartan and Amlodipine TARGET	Losartan and Amlodipine	Centro Universitario de Ciencias de la Salud, Mexico	marketed	Angiotensin II receptor antagonist + Calcium channel blocker combination	AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor antagonist + Calcium channel blocker combination class)

Centro Universitario de Ciencias de la Salud, Mexico · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Losartan and Amlodipine — Competitive Intelligence Brief. https://druglandscape.com/ci/losartan-and-amlodipine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab